Evidence method
Level · gp.fundamentals.capex_revenue_ratio
10.10% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
LCTX · Jun 30, 2026
Lineage Cell Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001193125-26-338064General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-677.64% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
-61.34% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-834.71% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
446.59% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
149.77% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History16 statesHistory building
Sep 30, 20220/5 normalizedLevel 3Dec 31, 20220/6 normalizedLevel 3Mar 31, 20230/6 normalizedLevel 3Jun 30, 20230/6 normalizedLevel 3Sep 30, 20230/7 normalizedLevel 3Dec 31, 20230/7 normalizedLevel 3Mar 31, 20240/6 normalizedLevel 3Jun 30, 20240/6 normalizedLevel 3Sep 30, 20244/6 normalizedLevel 3Dec 31, 20245/6 normalizedLevel 3Mar 31, 20255/6 normalizedLevel 3Jun 30, 20255/6 normalizedLevel 3Sep 30, 20256/6 normalizedLevel 3Dec 31, 20256/6 normalizedLevel 3Mar 31, 20266/6 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 3.19%
- Current
- 10.10%
- Delta
- 6.91%
- Previous
- -468.29%
- Current
- -677.64%
- Delta
- -209.35%
- Previous
- 14.85%
- Current
- -61.34%
- Delta
- -76.19%
- Previous
- -440.17%
- Current
- -834.71%
- Delta
- -394.53%
- Previous
- 245.45%
- Current
- 446.59%
- Delta
- 201.14%
- Previous
- 67.94%
- Current
- 149.77%
- Delta
- 81.82%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Compared To · Biological Products, (No Diagnostic Substances) peers →Has State · Lineage Cell Therapeutics, Inc. →Transitioned To · LCTX Fundamental State →Transitioned To · LCTX CAPEX_INTENSITY_INCREASED →Transitioned To · LCTX CASH_GENERATION_DECREASED →Transitioned To · LCTX GROWTH_DECREASED →Transitioned To · LCTX PROFITABILITY_DECREASED →Transitioned To · LCTX R_AND_D_INTENSITY_INCREASED →Transitioned To · LCTX SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.